Stem Cell Therapy to Improve Burn Wound Healing

A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds

This study will determine the safety of allogeneic stem cell therapy from healthy donors, for 2nd degree burn wounds of less than 20% Total Body Surface Area (TBSA), at four different dose levels.

Clinical evaluation will take place every 1 to 4 weeks intervals until wound closure, and then monthly for 6 months following the last administration of MSCs.

Once the safety and dose-response analysis in Phase 1 is completed, an expanded trial will be initiated to better examine the efficacy of MSC therapy in 2nd degree burn wounds. Phase 1 will establish the maximum safe dose that will be used in the Phase II trial.

Study Overview

• Status: Completed
• Conditions: Skin Burn Degree Second
• Intervention / Treatment: Biological: Allogeneic (MSC's) Application to the Burn Wounds

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Miami, Florida, United States, 33136
      • University of Miami

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

- Donors:

Eligibility Criteria:

• No history of malignancy
• No active coagulopathy and/or hypocoagulable state
• No history of cardio/pulmonary conditions
• Negative tests for Hepatitis A, Hepatitis B, Hepatitis C, RPR, HIV 1 / 2, HTLV I/II, Chagas Disease, NAT for HCV, HIV and WNV.
• Hemoglobin ≥ 13.0 g/dL
• Platelet count 140,000 to 440,000/ul
• WBC 3.0 to 11.0 K/ul
• BNP ≤ 100 pg /mL
• No anomalies on the CBC and differential suggestive of a hematopoietic disorder
• Creatinine ≤ 1.5 mg/dL
• ALT ≤ 112 IU/L
• AST ≤ 100 IU/L
• Bilirubin < 1.5 mg/dL
• No diabetes
• Systolic blood pressure ≤ 170
• Diastolic blood pressure ≤ 90
• No history of autoimmune disorders

Recipients:

Inclusion Criteria:

1. Male or female subjects 18 years of age or older with Superficial, Intermediate or Deep 2nd Degree Burn Wounds
2. Injury within the prior 7 days
3. Subjects must understand and give written informed consent.
4. Subjects must agree to have biopsies performed as per protocol
5. Subjects must be accessible for weekly wound treatment and assessment visits
6. Males and females must agree to use an acceptable method of contraception. Exceptions will be females of non-childbearing age and monogamous males who are partners of females of non-childbearing age. Acceptable methods of birth control include; history of sterilization, birth control pills, depoprogesterone injections, a barrier contraceptive such as a condom with or without spermicide cream or gel, diaphragms or cervical cap with or without spermicide cream or gel, or an intrauterine device (IUD).

7. Maximum wound size limited to:

   • Single wound: ≤ 5% body surface area (BSA)
   • Multiple wounds treated in a defined anatomical region with ≤ 20% cumulative BSA.
8. Diabetic subjects: HbA1c ≤ 8%

Exclusion Criteria:

1. Solely 1st degree or solely 3rd degree burns
2. Subjects with superficial 2nd degree burn who are expected to heal within 2 weeks post standard therapy
3. Evidence of active infection at the wound site
4. Evidence of significant wound healing prior to treatment
5. Wound located in the area of fingers, toes, face, or perineum
6. Wound where 75% or more extends across joints
7. Electrical or chemical burns
8. Have any requirement for the use of systemic steroids or immunosuppressive
9. Subjects Allergic to human albumin, streptomycin, or penicillin
10. Be a pregnant female or nursing mother
11. Subjects who are known or found to be HIV positive
12. Current history of alcohol or substance abuse or history of alcohol or substance abuse requiring treatment within the past 12 months

13. Patients with severe medical conditions

    1. Malignancy (other than non melanoma skin cancer) not in remission or in remission less than 5 years
    2. Life expectancy less than two years
    3. Severe cardiopulmonary disease restricting ambulation to the clinical facility
14. WBC <3 or > 10 x10⁹/L, Hgb < 9g/dL, platelets count 100x10⁹/L or less, serum creatinine > 1.5 times the upper normal limit, AST or ALT > 2.5 times the upper normal limit.
15. Subjects with abnormal bilirubin levels.
16. Subjects with abnormal PT/INR laboratory values while not on chronic anticoagulant treatment which can be held for minor surgical procedures
17. Those with a known history of coagulopathy
18. Subjects who are potential recipients of tissue or organ transplantation
19. Subjects with circulating Hepatitis B antigen and/or who are seropositive for Hepatitis C antibody
20. History of poor compliance, unreliability

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Allogeneic (MSC's) Application to the Burn Wounds; Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose. Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.

Biological: Allogeneic (MSC's) Application to the Burn Wounds; Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose; Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.; Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.; Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.; Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm. Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.; Other Names: Stem Cells Application to the Burn Wounds

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.	The study will consist of a dose escalation phase consisting of four dose levels. Each dose level will compare the safety of administering allogeneic MSCs, with 5 patients per group.	1.5 years

Collaborators and Investigators

• Sponsor: E.Badiavas
• Collaborators: United States Department of Defense
• Investigators: Principal Investigator: Carl Schulman, MD, PhD, University of Miami

Publications and helpful links

General Publications

• Maranda EL, Wang MX, Shareef S, Tompkins BA, Emerson C, Badiavas EV. Surgical management of leukoderma after burn: A review. Burns. 2018 Mar;44(2):256-262. doi: 10.1016/j.burns.2017.05.004. Epub 2017 Jun 8.

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2014
• Primary Completion (Actual): March 18, 2019
• Study Completion (Actual): March 18, 2019

Study Registration Dates

• First Submitted: April 1, 2014
• First Submitted That Met QC Criteria: April 1, 2014
• First Posted (Estimate): April 4, 2014

Study Record Updates

• Last Update Posted (Actual): April 30, 2020
• Last Update Submitted That Met QC Criteria: April 28, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Burn wound; Skin Burn Degree Second; Second degree Burn
• Additional Relevant MeSH Terms: Wounds and Injuries; Burns
• Other Study ID Numbers: 20120925

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No